Plant Name: Citrus medica
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NMUR2; | |
| FFAR1; FFAR4; ADRA2C; ADRA2A; HTR1A; | |
| PTPN1; | |
| GAA; BCHE; ACHE; | |
| TDP1; BLM; HPGD; GFER; HSD17B10; ALOX15; ALDH1A1; UBE2N; POLB; | |
| TRPA1; | |
| MAPK1; | |
| CA12; CA9; CA13; CA7; CA4; | |
| PPARA; PPARD; PPARG; | |
| THRB; | |
| KDM4E; | |
| PTGS1; | |
| CASP1; CASP7; | |
| HIF1A; | |
| ABCG2; | |
| RAB9A; NPC1; LMNA; FABP3; XPO1; MAPT; THPO; | |
| L3MBTL1; SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | UBE2N | Ubiquitin-conjugating enzyme E2 N | P61088 | CHEMBL6089 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
| Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | XPO1 | Exportin-1 | O14980 | CHEMBL5661 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.047E-13 | 3.663E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.299E-13 | 5.062E-09 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.872E-11 | 5.679E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.912E-11 | 5.679E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 9.115E-11 | 1.103E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, PTGS1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.565E-10 | 4.104E-07 | CA12, CA13, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.721E-10 | 5.227E-07 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.053E-09 | 1.797E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:1901700; response to oxygen-containing compound | 7.754E-09 | 4.221E-06 | BCHE, BLM, CA9, CASP1, CYP1A1, CYP1A2, CYP1B1, FABP3, FFAR1, FFAR4, HPGD, MAPK1, POLB, PPARA, PPARD, PPARG, TRPA1, TSHR |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.863E-08 | 1.417E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.863E-08 | 1.417E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.477E-08 | 2.650E-05 | CA12, CA13, CA4, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.720E-08 | 3.956E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.551E-07 | 6.621E-05 | CA12, CA13, CA4, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 2.075E-06 | 6.389E-04 | ADRA2A, BCHE, CA9, CYP1A2, FABP3, FFAR4, HPGD, NPC1, PPARA, PPARG, TSHR |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.356E-06 | 6.999E-04 | BLM, CA12, CA13, CA4, CA7, CA9, L3MBTL1, PPARA, PPARD, PPARG, PTPN1, THRB |
| BP | GO:0007610; behavior | GO:0007610; behavior | 2.532E-06 | 7.352E-04 | BCHE, GAA, HIF1A, HTR1A, MAPK1, MAPT, NMUR2, NPC1, PPARA, THRB |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 7.651E-06 | 1.915E-03 | ABCG2, ACHE, ADRA2A, ADRA2C, BCHE, BLM, CASP1, HPGD, L3MBTL1, MAPK1, MAPT, PPARG, RAB9A, SMN1, SMN2, TRPA1 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 7.961E-06 | 1.970E-03 | ACHE, BCHE |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 1.119E-05 | 2.518E-03 | ABCG2, ADRA2A, CA12, CA7, FABP3, FFAR1, HIF1A, MAPK1, NMUR2, NPC1, PPARG, TRPA1 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.133E-05 | 2.518E-03 | PPARA, PPARD, PPARG, THRB |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 1.386E-05 | 2.983E-03 | ALDH1A1, CYP19A1, CYP1A1, CYP1B1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 1.444E-05 | 3.053E-03 | CYP1A1, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.880E-05 | 3.826E-03 | CYP19A1, FFAR4, PPARA, PPARD, PPARG |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 2.205E-05 | 4.366E-03 | ACHE, CYP19A1, CYP1A1, CYP1A2, GFER, HIF1A, HPGD, L3MBTL1, MAPK1, POLB, PPARA, PPARD, PPARG |
| CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 2.272E-05 | 4.457E-03 | ABCG2, ACHE, BLM, CA13, CA4, CASP1, CASP7, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, GAA, GFER, HIF1A, HSD17B10, KDM4E, L3MBTL1, LMNA, MAPK1, MAPT, NPC1, POLB, PPARA, PPARD, PPARG, PTGS1, PTPN1, RAB9A, SMN1, SMN2, TDP1, THRB, UBE2N, XPO1 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.384E-05 | 4.475E-03 | CYP2D6, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 2.383E-05 | 4.475E-03 | PPARA, PPARD, PPARG, THRB |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.384E-05 | 4.475E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 2.384E-05 | 4.475E-03 | ADRA2A, ADRA2C |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.802E-05 | 5.127E-03 | CYP1A1, POLB, PPARG |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.716E-05 | 6.473E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0035902; response to immobilization stress | 4.238E-05 | 7.098E-03 | CYP1A1, CYP1A2, PPARG |
| BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 4.759E-05 | 7.791E-03 | ADRA2A, ADRA2C |
| BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 4.759E-05 | 7.791E-03 | ADRA2A, ADRA2C |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.759E-05 | 7.791E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 5.422E-05 | 8.618E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 5.910E-05 | 9.258E-03 | BLM, CASP7, CYP1A1, CYP1B1, MAPK1, NPC1, PPARG |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.323E-08 | 1.100E-06 | CYP2C9; CYP2D6; ALOX15; HTR1A; MAPK1; CYP2C19; PTGS1 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 7.877E-10 | 1.119E-07 | CA12; CA4; CA7; CA9; CA13 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.474E-08 | 1.047E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.826E-08 | 1.713E-06 | CYP2C9; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 9.741E-08 | 2.766E-06 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 5.355E-07 | 1.267E-05 | CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.513E-07 | 1.930E-05 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.284E-06 | 2.278E-05 | CYP2C9; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.536E-05 | 4.001E-04 | CYP2C9; ALOX15; CYP2C19; PTGS1 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.097E-04 | 1.416E-03 | THRB; HTR1A; NMUR2; ADRA2C; ADRA2A; TSHR |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 3.875E-05 | 5.502E-04 | FABP3; PPARG; PPARA; PPARD |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.732E-04 | 4.799E-03 | CYP2C9; GAA; CYP1A2; ALOX15; ALDH1A1; CYP1A1; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.809E-04 | 2.141E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 3.520E-04 | 3.845E-03 | CYP1A1; CYP1B1; CYP19A1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.174E-03 | 1.042E-02 | CASP7; MAPK1; MAPT; HSD17B10 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.182E-03 | 1.823E-02 | HTR1A; MAPK1; PPARA; TSHR |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.155E-03 | 1.042E-02 | CASP7; CASP1; MAPK1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.201E-03 | 3.140E-02 | THRB; MAPK1; HIF1A |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.753E-03 | 4.794E-02 | CASP7; LMNA; MAPK1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 2.874E-03 | 2.268E-02 | MAPK1; PPARG |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; MAPK1; CA9; XPO1; ACHE |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; MAPK1; CA9; XPO1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| NA: NA | Anxiety disorders | NA | HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR1A; CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | HTR1A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| NA: NA | Cervical dystonia | NA | HTR1A |
| NA: NA | Bulimia nervosa | NA | HTR1A |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | HTR1A; ADRA2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HTR1A; ACHE; MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR1A |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ADRA2C; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
| NA: NA | Episode | NA | HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; FFAR1; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR1A; ADRA2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRA2C |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR1A; HTR1A |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR1A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA2C; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | THRB |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; THRB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB |
| NA: NA | Social phobia | NA | HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR1A; HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | HTR1A; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | HTR1A; ADRA2C; ADRA2A; PTGS1; TRPA1; ACHE |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PPARG |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR1A; CYP3A4; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; FFAR1; PPARD; PPARG; PPARG |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | HTR1A; HTR1A; ADRA2C; ACHE; ACHE; ACHE; MAPT; PPARG; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | HTR1A |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRA2C |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; PPARD; PPARD; ADRA2C; PPARG |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR1A |
| NA: NA | Schizoaffective disorder | NA | HTR1A |